Gilead gets FDA breakthrough therapy status for magrolimab in MDS

Gilead gets FDA breakthrough therapy status for magrolimab in MDS

Source: 
Pharmaceutical Business Review
snippet: 

Gilead Sciences has been given breakthrough therapy designation for magrolimab from the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS) in newly diagnosed patients.